GlassScriptPhysician profile
Robert G Jakubowski
NPI 1780654475
$4,011.44
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $246 · 2021: $980 · 2022: $1,131 · 2023: $1,128 · 2024: $27.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,108 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27.00 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.20 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27.00 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $676.88 | 2019-2023 | Otezla, Repatha |
| Abbvie INC. | $662.11 | 2021-2023 | |
| Lilly USA, LLC | $403.36 | 2020-2023 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $291.63 | 2019-2023 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $219.81 | 2021-2023 | |
| Pfizer INC. | $214.13 | 2019-2023 | |
| Medtronic, INC. | $176.00 | 2022 | |
| Avanir Pharmaceuticals, INC. | $147.91 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $131.25 | 2019-2023 | Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $129.89 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.51 | 2020-2022 | |
| Glaxosmithkline, LLC. | $93.23 | 2022-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $80.26 | 2022-2023 | Nuedexta |
| Astrazeneca Pharmaceuticals LP | $59.10 | 2022-2023 | Farxiga |
| Scilex Pharmaceuticals INC. | $58.85 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.49 | 2022-2023 | Synjardy, Jardiance |
| Amarin Pharma, INC. | $40.99 | 2021 | |
| Abbott Laboratories | $40.33 | 2022-2023 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $39.64 | 2022 | |
| Astellas Pharma US INC | $39.04 | 2022 | |
| Pacira Therapeutics, INC. | $35.47 | 2019 | |
| Tersera Therapeutics LLC | $31.28 | 2019 | |
| Allergan, INC. | $28.72 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $28.03 | 2021 | |
| Becton, Dickinson and Company | $27.00 | 2024 | Site-Rite |
| Merck Sharp & Dohme LLC | $24.35 | 2022 | |
| Medtronic USA, INC. | $23.28 | 2019-2020 | |
| Exact Sciences Corporation | $23.20 | 2023 | Cologuard Collection Kit |
| Redhill Biopharma INC. | $21.28 | 2020 | |
| Nestle Healthcare Nutrition INC. | $18.95 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.98 | 2022 | |
| Almatica Pharma LLC | $17.94 | 2023 | Gralise, Loreev Xr |
| Arbor Pharmaceuticals, INC. | $16.99 | 2019 | |
| Collegium Pharmaceutical, INC. | $15.75 | 2019 | |
| Intuity Medical INC | $14.09 | 2022 | |
| Vertical Pharmaceuticals, LLC | $12.56 | 2019 | |
| Vistapharm, INC. | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Jakubowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.